A strategic collaboration marking the beginning of a new era in the field of medical
cannabis, with a focus on personalized care and the empowerment of healthcare
professionals through modern tools.
Athens, 03 June 2025
Curity Pharma, a new and rapidly growing Greek medical cannabis company, announces the establishment of a strategic partnership with Galenica S.A., one of the most reliable and well-established providers of pharmaceutical products and services in Greece. The collaboration concerns the commercial availability and distribution of Curity Pharma’s medical cannabis products in the Greek market. Curity Pharma’s entry into the medical cannabis sector is marked by a differentiated portfolio of eight products, designed to enable physicians to select the most suitable formulation for each patient based on both immediate and long-term needs. The company aims to offer modern products founded on scientific evidence, quality, and
safety. With many years of experience and expertise in the development, import, distribution, and support of innovative pharmaceutical products, Galenica embraces Curity Pharma’s vision for a new era in medical cannabis. Galenica significantly contributes to this initiative by leveraging its extensive network, scientific expertise, and commercial strength.
Mr. Manos Chatiras, Co-Founder, President, and CEO of Curity Pharma, stated:
“”At Curity Pharma, we believe in medical care that is scientifically grounded and personalized for everyone. Our collaboration with Galenica, a pharmaceutical company with a long-standing presence and prestige in the pharmaceutical sector, forms the foundation of our entry into the Greek market, aiming to meaningfully contribute to improving patients’ quality of life through the responsible use of medical cannabis.”
Mr. Nikolaos Varelas, Chairman of the Board and CEO of Galenica S.A., said:
“As a wholly Greek pharmaceutical company with over 50 years of commitment to health, Galenica remains dedicated to innovation and to ensuring patients’ access to treatments that meet modern medical needs.
Medical cannabis is internationally recognized as an important therapeutic option for
specific conditions, and its responsible use aligns with our vision of comprehensive, human-
centered healthcare. Our strategic partnership with Curity—a dynamic Greek company—confirms our commitment to supporting Greek production and entrepreneurship, while investing in therapeutic solutions that add value to both patients and the national economy.”
About Curity Pharma S.A.
Curity Pharma is a vertically integrated medical cannabis company located on a privately owned 67,000 m² site in the Industrial Area of Larissa. Its infrastructure includes a pioneering 5,000 m² hybrid greenhouse unit for the cultivation of medical cannabis, as well as a 1,800 m² production unit operating in compliance with Good Manufacturing Practice (GMP) standards. Curity Pharma remains committed to delivering safe and effective therapeutic solutions while strengthening Greece’s position as a key hub in the European medical cannabis industry.
